Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New approach by Cornell researcher could enable treatment of some cancers with retinoic acid with little or no side effects

14.08.2002


For some time doctors have been using a vitamin A derivative, retinoic acid (RA), to treat several cancers, particularly prostate cancer and leukemia, and they are now experimenting with the drug to treat breast cancer. The great drawback to RA, however, is that it requires high levels of the medication in order to turn genes "on" and "off," often triggering devastating and potentially fatal side effects.



Now, a Cornell University biochemist has learned how to make tumor cells up to 1,000 times more sensitive to RA so that much smaller doses would be required to flick the "on" and "off" switch (a process known as the induction of gene expression).

"This novel strategy for regulating the anticarcinogenic activity of retinoic acid has potential not only for treating tumors but also, perhaps, for protecting high-risk patients preventively," says Noa Noy, a professor of nutritional sciences at Cornell. "We have discovered that a naturally occurring protein in the cell can dramatically enhance the ability of RA to inhibit the proliferation of breast cancer cells, so that much less RA -- perhaps even the amount naturally present in the body -- is required to suppress tumor development."


The new findings are described in two recent articles in Molecular and Cellular Biology (April and July 2002).

RA belongs to a class of compounds known as retinoids that play key roles in regulating gene transcription and, therefore, govern multiple functions in the body, such as cell division and differentiation, immune response and embryonic development. They also control the development and spread of cancer cells, and some, including RA, can inhibit tumor growth by preventing cancer cell proliferation. Retinoids are now in clinical trials for treatment of head, neck and breast cancers, as well as for diabetes, arteriosclerosis and emphysema.

In the body, RA activates a protein in cells known as retinoic acid receptor (RAR) that binds to certain DNA sequences and turns target genes on or off. A typical treatment with RA seeks to activate RAR in order to switch on favorable genes. However, at pharmacological doses, RA and other retinoids are highly toxic. Moreover, cancer patients frequently become resistant to RA therapy over time.

Noy decided to take a different approach by seeking to understand how the gene-transcription activity of RA is regulated by two proteins called cellular retinoic acid-binding proteins (CRABP-I and CRABP-II). These proteins were identified decades ago, but their exact functions remained obscure.

"We have found that as soon as RA binds to CRABP-II, the protein rapidly moves into the cell nucleus, unlike CRABP-I, which keeps RA out of the nucleus. Once in the nucleus, CRABP-II binds to RAR and channels RA to it, thereby activating the transcription factor to turn genes on or off," explains Noy.

Noy has found that CRABP-II greatly enhances the transcriptional activity of retinoic acid receptors by directly targeting RA to them. Therefore, she has been working on introducing CRABP-II to cells to treat cancer. She is looking into patenting her approaches.

Noy also has indications that CRABP-II can slow tumor growth in the presence of very small amounts of RA. In new, as yet unpublished, research, Noy -- in collaboration with nutritional sciences colleague Danny Manor, and Rodney Page and Alexander Nikitin of Cornell’s College of Veterinary Medicine -- studied the effectiveness of CRABP-II in mice with cancer. When tumors in the mice reached half a centimeter, one group received injections of a virus that expressed CRABP-II in the tumors.

"The rate of growth of tumors in the mice that received CRABP-II was dramatically slower," says Noy. "The implication here is that we may not even need to administer RA to treat tumors, but can make use of the RA already present in the body and use CRABP-II to sensitize the tumor to it," she observes.

Noy hopes to perfect the technique so that researchers can develop an approach to introduce CRABP-II in specific tissues and thereby influence target-gene expression.

The research was supported, in part, by the National Institutes of Health, the Swiss National Science Foundation and the Novartis Foundation.

Susan S. Lang | EurekAlert!
Further information:
http://www.nutrition.cornell.edu/faculty/noy.html

More articles from Health and Medicine:

nachricht Why might reading make myopic?
18.07.2018 | Universitätsklinikum Tübingen

nachricht Unique brain 'fingerprint' can predict drug effectiveness
11.07.2018 | McGill University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

Im Focus: Chemical reactions in the light of ultrashort X-ray pulses from free-electron lasers

Ultra-short, high-intensity X-ray flashes open the door to the foundations of chemical reactions. Free-electron lasers generate these kinds of pulses, but there is a catch: the pulses vary in duration and energy. An international research team has now presented a solution: Using a ring of 16 detectors and a circularly polarized laser beam, they can determine both factors with attosecond accuracy.

Free-electron lasers (FELs) generate extremely short and intense X-ray flashes. Researchers can use these flashes to resolve structures with diameters on the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

Machine-learning predicted a superhard and high-energy-density tungsten nitride

18.07.2018 | Materials Sciences

NYSCF researchers develop novel bioengineering technique for personalized bone grafts

18.07.2018 | Life Sciences

Why might reading make myopic?

18.07.2018 | Health and Medicine

VideoLinks
Science & Research
Overview of more VideoLinks >>>